Latest AP26113 Stories
SAN DIEGO and BARCELONA, Spain, Nov.
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, May 20, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts'
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 2, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts'
Singapore, Aug 6, 2013 - (ACN Newswire) - A team of scientists led by Associate Professor Zeng Qi(1) from A*STAR's Institute of Molecular and Cell Biology (IMCB) have discovered a new biomarker which will
ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC).
For scientists to improve cancer treatments with targeted therapeutic drugs, they need to be able to see proteins prevalent in the cancer cells.
Several new first-in-man studies for drugs targeted against a range of cancers were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
- A gift; a largess; a gratuity; a present; a dole.